Why Annex 21 Is an Important Commercial Risk Point in EU Market Entry

For many pharmaceutical and biotech companies, securing approval for a medication is seen as the final regulatory milestone before commercialisation. In practice, however, approval is only one part of the journey. The transition from approval to placing a product on the European market introduces a different set of challenges, and this is where Annex 21 of European Union’s (EU) Good Manufacturing Practice (GMP) guidelines becomes important.

Annex 21 governs the import of medicinal products into the EU. It is often treated as a procedural requirement, another compliance box to be ticked before distribution can begin. But this interpretation significantly underestimates its impact. In reality, Annex 21 is where regulatory intent meets operational execution, and where many companies encounter delays, unexpected costs, and avoidable risk.

The issue is not that Annex 21 is particularly complex on paper. The challenge is that it imposes a level of accountability that extends beyond documentation and into the design and control of the entire supply chain. For organisations entering the EU market, particularly those based in the US or Asia, this shift is often not fully appreciated until it begins to affect timelines and product availability.

Why Is Annex 21 Perceived as Just a Formality?

A common assumption is that once a product has been manufactured, tested, and released in its country of origin, the remaining steps required to enter the EU are largely administrative. The product is considered ready, and import is viewed as a logistics exercise rather than a regulated activity in its own right.

Under Annex 21, this is not the case. Import into the EU is treated as a manufacturing activity, and the responsibility for ensuring compliance sits with the holder of a Manufacturing Import Authorisation (MIA). This includes oversight of the supply chain, verification of test results, and, ultimately, certification of each batch by a Qualified Person before it can be released to the market.

What this means in practice is that the Qualified Person is not simply reviewing a few manufacturing documents. They are required to have confidence in the integrity of the product and the processes behind it, including activities that may have taken place entirely outside the EU. That confidence must be justified, documented, and defensible.

What Does Annex 21 Require in Practice?

At its core, Annex 21 establishes that the Qualified Person responsible for certification must ensure that each batch has been manufactured and tested in accordance with EU GMP, regardless of where those activities took place. This includes the ability to rely on testing performed in third countries, where this is permitted under an applicable Mutual Recognition Agreement, and where the controls, oversight, and technical agreements in place support that reliance.

However, the requirement does not stop at analytical data. The Qualified Person must also consider factors such as the transport of the product into the EU, any deviations that occurred during shipment, and the overall integrity of the supply chain. The responsibility extends from the point of manufacture through to the point of certification, creating a continuous chain of accountability.

This is where Annex 21 becomes operational rather than theoretical. It requires that the systems, agreements, and oversight mechanisms are not only defined but also functioning effectively in practice.¹ Gaps that may not be visible at the documentation level can become critical when assessed through the lens of batch certification.

Where Do Companies Encounter Problems?

In working with organisations entering the EU market, several recurring issues tend to arise. These are not typically due to a lack of regulatory knowledge, but rather a disconnect between regulatory planning and commercial or operational decision-making.

One of the most common challenges is treating the EU as an extension of existing markets, assuming that processes designed for FDA or other regulatory frameworks can be applied with minimal adjustment. While there are similarities, the role of the Qualified Person and the expectations under Annex 21 introduce a different model of accountability that requires specific planning. Another issue is the late identification of the import model. Companies often focus on manufacturing and regulatory approval, leaving the structure of EU import to be addressed closer to launch. This can result in insufficient time to establish robust technical agreements, qualify supply chain partners, or align testing strategies with EU expectations.

There is also frequent over-reliance on third-party data, without a clear framework for how that data will be assessed and accepted by the Qualified Person. Reliance on third-country testing is permissible, where permitted under an applicable Mutual Recognition Agreement, but it must be justified through a combination of oversight, knowledge of the testing site, and confidence in the systems in place. Similarly, there is often an assumption that pre-existing audit reports can be leveraged, even where they may not be suitable or fully aligned with EU GMP expectations. Without this level of assurance, certification becomes difficult or delayed.

Finally, the role of the MIA holder is sometimes underestimated. Rather than being viewed as a strategic partner in the import process, the MIA is treated as a transactional requirement. This can limit the level of integration needed to ensure that the supply chain is designed in a way that supports compliant and efficient certification.

What Is the Commercial Impact of Getting it Wrong?

The consequences of these gaps are not confined to regulatory findings. They have direct commercial implications, particularly at the point of launch.

Delays in batch certification can prevent a product from being released to the market, even when manufacturing and testing have been completed. In some cases, additional testing or investigation may be required to address uncertainties, leading to increased costs and extended timelines. Supply chain disruptions can occur if products are held pending certification, affecting distribution and availability.

More broadly, uncertainty in the import model can introduce risk into forecasting and launch planning. Commercial teams may be working towards timelines that are not aligned with the realities of EU batch certification, creating pressure at a critical stage of product introduction.

These issues are not uncommon, and they are rarely the result of a single failure. More often, they arise from a series of small misalignments between regulatory expectations and operational execution that become visible only when the product reaches the point of import.

What Is a More Effective Approach to Annex 21?

Organisations that navigate Annex 21 most effectively tend to approach it not as a final step but as an integral part of their EU market-entry strategy. This involves defining the import model early, including the role of the MIA holder and the approach to Qualified Person certification. It requires aligning manufacturing, testing, and supply chain design with EU expectations from the outset, rather than adapting them later. It also means establishing a level of oversight and collaboration that allows the Qualified Person to have confidence in the data and processes supporting each batch.

In practical terms, this often includes early engagement with the MIA holder, clear technical agreements that reflect actual operations, and a proactive approach to understanding how third-country activities will be assessed under EU GMP. The goal is not simply to meet regulatory requirements, but to create a system that supports consistent and efficient certification.

From Regulatory Requirement to Commercial Reality

Annex 21 is sometimes viewed as a narrow regulatory annex, but its implications are much broader. It sits at the intersection of regulatory compliance, supply chain design, and commercial execution. For companies entering the EU market, it represents the point at which strategy is tested against reality.

Those who treat it as a late-stage requirement often encounter friction at the point of import. Those who integrate it into their planning from the outset are better positioned to achieve a smoother transition from approval to market.

Ultimately, Annex 21 is not simply about ensuring that products can be imported into the EU. It is about ensuring that they can be released to the market with confidence, supported by a system that is robust, transparent, and aligned with regulatory expectations. In that sense, it is less a regulatory hurdle and more a defining element of a successful EU market entry strategy.

Charley Maxwell is the managing director at Orion GXP Consulting.

References

1. Orion GxP Consulting. Importing medicines into the European Union. Orion GxP. Published November 11, 2025. Accessed April 14, 2026. https://oriongxp.com/article/importing-medicines-into-the-european-union